Treats clinically important hypotension occurring in the setting of anesthesia. ANDA 216740, held by Baxter Hlthcare Corp. Ephedrine Sulfate.
As of Nov 16, 2026, ANDA 216740 (Ephedrine Sulfate), held by Baxter Hlthcare Corp, was first approved by FDA on Jul 8, 2026, with 0 approved supplements and 0 published complete response letters.
Ephedrine Sulfate Injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 8, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ephedrine Sulfate50MG/ML (50MG/ML) · solution;intravenous | Ephedrine Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters